News

12 March 2013
CYTOO is proud to announce that its adhesive micropatterns are mentioned in more than 30 publications, covering a wide range of research areas, and in prestigious journals such as Nature, Plos One, Developmental Cell and Journal of Cell Biology. Two thesis mentioning CYTOO’s technology have also been defended. Among major publications, some breakthroughs can be highlighted: Kristine Schauer’s Organelle Map (finalist of the SLAS 2013 Innovation Award) Ved Sharma’s study of tumor cell migration and pairing Amandine Pitaval’s fine control of primary cilia...
28 January 2013
CYTOO sponsors the Motility subgroup at the Biophysical Society meeting (Feb 02-06, Philadelphia) CYTOO will attend the Biophysical Society (BPS) 57th Annual Meeting in Philadelphia, Pennsylvania, USA to present its innovative Cell Culture Platform, based on adhesive micropatterns. After the recent launch of the CYTOOplates Motility, specifically designed to study cell migration for screening applications in both oncology and drug discovery, the company has the great pleasure to sponsor the Motility subgroup.  
07 January 2013
CYTOO's 2D+ Technology and Institut Curie’s Organelle Map in the limelight at SLAS 2013 (Jan 12-16, Orlando) CYTOO will attend the Society for Laboratory Automation and Screening (SLAS) 2013 conference in Orlando, Florida, USA, to present the 2D+ Solutions, opening fresh perspectives for cell based assay development in drug discovery. A $10,000 cash prize will be attributed during SLAS 2013, and recognizes extraordinary achievement in innovative laboratory science and technology. Kristine Schauer’s Organelle Map figures among the nine 2013 SLAS Innovation Award ...
02 January 2013
CYTOO launches 2D+ Solutions at High Content Analysis (HCA), January 08-11, 2013 CYTOO will launch the 2D+ Solutions at the High Content Analysis (HCA) Annual Meeting in San Francisco, USA. 2D+ Solutions opens fresh perspectives for cell based assay development in drug discovery. CYTOO’s Custom Solutions bring expertise, resources and technology to address current bottlenecks in cell based assay development and screening.  
10 December 2012
Exclusive offer at American Society for Cell Biology (ASCB), December 15-19, 2012 CYTOO will offer a significant discount on all CYTOO Motility products at the ASCB 2012 Annual meeting in San Francisco: attendees are invited to visit ASCB Booth #329 for this exclusive offer!  
03 December 2012
CYTOO's Motility Plates to study cell migration to be launched at American Society for Cell Biology (ASCB), December 15-19, 2012 CYTOO will launch the CYTOOplates Motility, based on CYTOO’s 2D+ Cell Culture Platform with its adhesive micropatterns, at the ASCB 2012 Annual meeting in San Francisco, USA. After sponsoring last year’s “World Cell Race”, showcased at ASCB 2011 with huge success, CYTOO returns to ASCB 2012 to launch a new product to study cell migration for screening applications in both oncology and drug discovery
10 November 2012
We ask for a rapid feedback (6 questions) on your potential interest on new assay development kits currently imagined by CYTOO, with application to Toxicology for Drug/Lead screening. Our 2D+ technology, and the related 3 kits (Proximal Renal Tubule Assay, Hepatotoxicity Assay, Drug-Drug interaction Assay) are described at the beginning of the survey. We would like to recognize your help and send a $20 Starbucks card to the first 50 responders, we are anxious to hear from you... The survey is closed, thank you for your participation!
17 October 2012
CYTOO announces today new results that demonstrate the ability of the Company’s 2D+ Cell Culture Platform to reproduce in vivo conditions to analyze tumor cell motility, and in particular to study fibrillar ECM-dependent tumor cell-macrophage pairing and migration involved in tumor metastasis. These results have recently been published in the first issue of the journal IntraVital, edited by Landes Bioscience.  
05 October 2012
We ask for a rapid feedback (6 questions) on your potential interest on new assay development kits currently imagined by CYTOO, with application to Oncology Drug Screening. We would like to recognize your help and send a $20 Starbuck card to the first 50 responders. Thank you for your help on this short survey! The survey is closed, thank you for your participation!
21 September 2012
CYTOO has teamed up with Cenix BioScience and three European academic partners to challenge the current limits of high throughput (HT) RNAi screening in cultured cells. The SME-driven project, coordinated by CYTOO, aims to combine HT applications of RNAi with an emerging new technology for normalizing cultured cells' behavior by growing them on adhesive micropatterns. Currently in its first year of development, the consortium is seeking to put together an end user committee, with annual meetings, which would have privileged access to the consortium results, and which would provide precious...

Pages